NCIC Clinical Trials Group

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma

Phase 2

Completed

Conditions: Kidney Cancer

First Posted Date: 2004-01-12

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 19

Registration Number: NCT00075660

Locations: 🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada
🇨🇦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

and more 5 locations

Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease

Phase 3

Completed

Conditions: Hodgkin Lymphoma

Interventions: Biological: bleomycin sulfate
Drug: dacarbazine
Drug: doxorubicin hydrochloride
Drug: vinblastine
Radiation: radiation therapy

First Posted Date: 2003-11-21

Last Posted Date: 2020-04-14

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 405

Registration Number: NCT00002561

Locations: 🇨🇦
Regional Health Authority B, Zone 2, Saint John, New Brunswick, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇬🇧
Royal South Hants Hospital, Southampton, United Kingdom

and more 19 locations

ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2003-09-17

Last Posted Date: 2020-04-06

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 40

Registration Number: NCT00025116

Locations: 🇨🇦
Tom Baker Cancer Center - Calgary, Calgary, Alberta, Canada
🇨🇦
Ontario Cancer Institute, Toronto, Ontario, Canada

MG98 in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-08-20

Last Posted Date: 2020-04-06

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 19

Registration Number: NCT00003890

Locations: 🇨🇦
Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Drug: exemestane
Drug: Placebo

First Posted Date: 2003-08-07

Last Posted Date: 2020-04-02

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 98

Registration Number: NCT00066586

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, United States
🇨🇦
Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
🇨🇦
Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada

and more 9 locations

Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: exemestane
Drug: anastrozole

First Posted Date: 2003-08-07

Last Posted Date: 2023-08-25

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 7576

Registration Number: NCT00066573

Locations: 🇨🇦
Stronach Regional Health Centre at Southlake, Newmarket, Ontario, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
Credit Valley Hospital, Mississauga, Ontario, Canada

and more 36 locations

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Biological: pegfilgrastim
Drug: docetaxel
Drug: epirubicin hydrochloride

First Posted Date: 2003-08-07

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 93

Registration Number: NCT00066443

Locations: 🇨🇦
Atlantic Health Sciences Corporation, Saint John, New Brunswick, Canada
🇨🇦
Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
CHA-Hopital Du St-Sacrement, Quebec City, Quebec, Canada

and more 2 locations

Combination Chemotherapy in Hodgkin's Disease or Non-Hodgkin's Lymphoma Not Responding to Previous Treatment

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-07-30

Last Posted Date: 2020-04-09

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 77

Registration Number: NCT00014209

Locations: 🇨🇦
Credit Valley Hospital, Mississauga, Ontario, Canada
🇨🇦
Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

and more 10 locations

Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Drug: rebimastat

First Posted Date: 2003-07-25

Last Posted Date: 2020-04-06

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 774

Registration Number: NCT00006229

Locations: 🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇦🇹
AKH Vienna, Vienna (Wien), Austria
🇺🇸
Memorial Hospital Cancer Center - Chattanooga, Chattanooga, Tennessee, United States

and more 66 locations

Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: CHOP regimen

First Posted Date: 2003-07-09

Last Posted Date: 2020-04-01

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 824

Registration Number: NCT00064116

Locations: 🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇨🇦
PEI Cancer Treatment Centre,Queen Elizabeth Hospital, Charlottetown, Prince Edward Island, Canada
🇨🇦
Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada

and more 22 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy